DifGen Pharmaceuticals is a US-based CDMO specializing in complex generics and advanced drug delivery systems, providing end-to-end solutions from product development through commercial manufacturing. Through its 2023 acquisition of Aveva Drug Delivery Systems Inc., DifGen gained a 455,000 sq. ft. US manufacturing footprint producing over 300 million transdermal patches annually, including controlled substances like buprenorphine transdermal systems.
complex generics, transdermal drug delivery, 505(b)(2) development, dissolvable films, controlled substances
2 sites worldwide
No certifications on file yet.
No reviews available yet.
No documents available.